

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Eckert & Ziegler Nuclitec GmbH	06/10/2010
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PerkinElmer, Inc.
<b>Street Address:</b>	940 Winter Street
<b>City:</b>	Waltham
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02451
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	5435937
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(781)663-5968
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	781-663-5786
<b>Email:</b>	kevin.oliver@perkinelmer.com
<b>Correspondent Name:</b>	Kevin A. Oliver, PerkinElmer, Inc.
<b>Address Line 1:</b>	940 Winter Street
<b>Address Line 4:</b>	Waltham, MASSACHUSETTS 02451
<b>NAME OF SUBMITTER:</b>	Kevin A. Oliver
<b>Total Attachments: 3</b> source=PatentAssignment(EckertZiegler)#page1.tif source=PatentAssignment(EckertZiegler)#page2.tif source=PatentAssignment(EckertZiegler)#page3.tif	

OP \$40.00 5435937

## ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS is entered into as of the 10<sup>th</sup> day of June, 2010, by and between Eckert & Ziegler Nuclitec GmbH, a company registered in Braunschweig, Germany ("Assignor"), and PerkinElmer, Inc., a Massachusetts corporation ("Assignee").

WHEREAS, Assignor owns all right, title and interest in and to and is the sole and exclusive owner of the patents listed on Schedule A, attached hereto and incorporated herein (the "Patents");

WHEREAS, by virtue of an asset purchase between AEA Technology PLC and Eckert & Ziegler Nuclitec GmbH, Assignor is the owner of the Patents; and

WHEREAS, by virtue of an asset purchase between Assignee and GE Healthcare UK Limited, Assignee is the exclusive licensee of the Patents; and,

WHEREAS, Assignor desires to assign and transfer to Assignee all of its right, title, and interest in and to the Patents, and Assignee is desirous of acquiring the same.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby assign, sell and transfer to Assignee, its successors and assigns, Assignor's entire right, title, and interest in and to the Patents, including any continuations, continuations-in-part, divisions, re-examinations, re-issues, and extensions, including any priority application or subsequently filed application based in whole or in part thereon, for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors and assigns, or other legal representatives, together with all income, royalties or payments due or payable as of the effective date of this assignment or thereafter, including without limitation all claims for damages by reason of past, present or future infringement or any unauthorized use thereof, with the right to sue for, and collect the same for Assignee's own use and benefit, and for the use and enjoyment of its successors, assigns and legal representatives. Assignor does further consent to the recordation of this Assignment by Assignee with a governmental agency or body in any applicable jurisdiction, any costs associated with such recordation being borne by Assignee.

This assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, each of which such successors and assigns shall be deemed a party hereto for all purposes hereof. This assignment shall be effective immediately upon its delivery to the Assignee. It is being understood that Assignor shall not be liable for any maintenance fees, including any surcharges for late payments, which are due after the date of this Agreement. As of 10 June 2010 and effective with this Assignment, Assignor and Assignee hereby agree to terminate, and discharge all obligations related thereto, that Patent License Agreement entered into between AEA Technology PLC and Amersham Biosciences UK Limited

(trading as GE Healthcare), dated 27 September 2005, to which the Assignor and Assignee have succeeded. Assignor does not make any representations or warranties with respect to the Patents. This assignment shall be executed in one or more counterparts, each of which may be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, Assignor and Assignee have executed this Assignment as of the date first written above.

PerkinElmer, Inc

Eckert & Ziegler Nucletec GmbH

By: [Signature]

By: [Signature]

Title: VP


Title: Managing Director

STATE OF Mass )  
COUNTY OF Suffolk )

On June 11, 2010, before me, Linda M. Byrnes personally appeared John L. Healy proved to me through satisfactory evidence of [Signature] to be the person whose name is subscribed to within the instrument, and acknowledged to me that s/he executed the same in her/his authorized capacity, and that by her/his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS by hand and official seal.

[Signature]  
(Signature of Notary)



SCHEDULE A

Country	Ctry No	Appln No	Appln Date	OPI No	OPI Dt	Grant No	Grant Date
Fluorescent compounds I							
ATe (Austria [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
BEe (Belgium [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
CA (Canada)	0	2089198	10. Feb 93		14. Aug 93	2089198	31. Aug 04
CHe (Switzerland[EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
DEe (Germany [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
EP (Europe)	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
FRe (France [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
GBe (Uni.Kingdom[EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
ITe (Italy [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
LLe (Luxembourg [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
NLe (Netherlands[EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
SEe (Sweden [EP])	0	93_300892.2	08. Feb 93	0556005A	18. Aug 93	0556005B	17. Apr 96
US (United States)	0	08/017674	12. Feb 93			5435937	25. Jul 95

## Fluorescent Compounds 2

ATe (Austria [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
BEe (Belgium [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
CA (Canada)	0	2176525	14. Mai 96		22. Nov 96	2176525	15. Apr 08
CHe (Switzerland[EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
DEe (Germany [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
EP (Europe)	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
FRe (France [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
GBe (Uni.Kingdom[EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
ITe (Italy [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
LLe (Luxembourg [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
NLe (Netherlands[EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99
SEe (Sweden [EP])	0	95 303551.6	25. Mai 95	0744451A	27. Nov 96	0744451B	21. Jul 99

AY